	US 12,343,426 B2
	Therapeutic hydrogels
Viktoria Molnar, Macroom (IE); Carolina Villarreal, Hopedale, MA (US); Bhanu Prasanth Koppolu, Cary, NC (US); Nivedita Swetha Ramkumar, Cork (IE); and Philip David Dorgan, Cork (IE)
Assigned to Boston Scientific Scimed, Inc., Maple Grove, MN (US)
Filed by Boston Scientific Scimed Inc., Maple Grove, MN (US)
Filed on Apr. 5, 2022, as Appl. No. 17/713,596.
Claims priority of provisional application 63/171,231, filed on Apr. 6, 2021.
Prior Publication US 2022/0313603 A1, Oct. 6, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/06 (2006.01); A61K 47/02 (2006.01); A61K 47/36 (2006.01); A61K 47/42 (2017.01)

CPC A61K 9/06 (2013.01) [A61K 47/02 (2013.01); A61K 47/36 (2013.01); A61K 47/42 (2013.01)]

20 Claims

1. A therapeutic hydrogel comprising: (a) an anionic polysaccharide, and (b) a branched polyamine, wherein the anionic polysaccharide is negatively charged at a pH of the therapeutic hydrogel, wherein the branched polyamine has a molecular weight that is less than 2000 g/mol, is positively charged and comprises two or more positively charged, primary amine groups at the pH of the therapeutic hydrogel, and wherein the branched polyamine ionically crosslinks the anionic polysaccharide.